It’s terrific you’re doing well on LDN, whether or not it is due to the LDN as you so carefully noted. I think there are ongoing efforts to initiate a LDN study. Here’s an abstract that you might want to share with your pharmacist: LDN Therapy in MS
. It presents a hypothesis about how LDN may work in MS.
the excitatory neurotoxicity of glutamate on neuronal cells and oligodendrocytes via activation of the alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid class of glutamate receptor is prevented. It is crucial that the medical community respond to patient needs and investigate this drug in a clinical trial.
And, trying to connect some dots, here’s a quote from the news
Dunmann posted yesterday.
The researchers showed myelin contains specialized receptors for glutamate, a neurotransmitter that transmits signals to brain cells. They also found chemicals that block the receptor can reduce myelin damage. "Such a mechanism may represent a potentially important therapeutic target in disorders in which myelin damage is a prominent feature,"
My interpretation is that there’s a definite connection between yesterday’s news and the hypothesis about how LDN may theoretically work. The research suggests blocking glutamate receptors may reduce myelin damage. The LDN hypothesis is based in part on preventing glutamate neurotoxicity on neurons and oligodendrocytes. I think oligodendrocytes are the myelin forming glial cells in the CNS. I’m not a scientist at all though so maybe one of the members more knowledgeable about LDN will comment. There is a need for LDN clinical trials and maybe yesterday’s finding will kick the impetus for those up a notch.
A safe, effective and relatively cheap drug that can make a difference to people with MS is definitely in order. I hope you continue to do well on it.